Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients.

Background: Cancer cells exhibit metabolic reprogramming often driven by aberrant Wnt/β-catenin signaling. Recent evidence suggests antiparasitic drugs can inhibit this pathway. Acupuncture Meridian Assessment (AMA), a modification of electroacupuncture according to Voll, measures electrical conductance at acupuncture points to guide therapeutic interventions. Objective: To evaluate clinical outcomes of AMA-guided antiparasitic and antifungal therapy in patients with advanced cancer. Methods: Six patients with stage IV cancers (breast, lung, prostate, glioblastoma, and multiple myeloma) underwent AMA evaluation between 2011 and 2022. Treatment protocols included combinations of ivermectin, mebendazole, praziquantel, niclosamide, and antifungals, selected based on AMA readings. Primary outcomes were overall survival and disease progression. Dental infections were addressed concurrently. Results: All six patients demonstrated prolonged survival, exceeding the expected conventional prognosis. The breast cancer patient achieved complete remission (30+ months disease-free). The multiple myeloma patient has been surviving 14 years with normalized biomarkers. The lung cancer patient has been surviving 10 years post-diagnosis with negative imaging. Both glioblastoma patients showed tumor regression with extended survival, although one glioblastoma patient died from a fall with head injury in 2025 after submitting this article. The prostate cancer patient is surviving and has achieved a PSA reduction from 32 to 0.3. No serious adverse events were reported. Conclusions: AMA-guided antiparasitic therapy showed promising outcomes in this small case series. These preliminary results warrant further study to evaluate the efficacy and safety of this integrative approach.